ClinicalTrials.gg
CompletedNCT06519968Updated Nov 17, 2025

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.

A Phase 1 interventional study of AZD4604 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of AZD4604 when administered as single or multiple inhaled doses to healthy Japanese and Chinese participants.

Read the detailed description

This study will comprise of two parts: Part 1 and Part 2

Part 1 will investigate the safety, tolerability, and PK of inhaled AZD4604 following single ascending and multiple doses in healthy Japanese participants.

Part 1a will include three single ascending dose (SAD) cohorts and Part 1b will include one multiple dose cohort.

Part 2 will investigate the safety, tolerability, and PK of inhaled AZD4604 following single ascending and multiple doses in healthy Chinese participants.

Part 2a will include two SAD cohort and Part 2b will include one multiple dose cohort.

Part 1a and Part 2a will comprise of:

  1. A Screening Visit within 28 days before dosing.
  2. A treatment period (Day 1 to Day 7)
  3. A final assessment on Day 7

Part 1b and Part 2b will comprise of:

  1. A Screening Visit within 28 days before dosing.
  2. A treatment period (Day 1 to Day 13)
  3. A final assessment on Day 13
02

Conditions studied

  • Healthy Participants

Keywords

  • Ascending doses
  • Multiple doses
  • JAK1 inhibitor
  • Chinese
  • Japanese
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants who are born in Japan, has 2 Japanese biological parents, 4 Japanese grandparents as confirmed by the interview and has lived outside Japan for less than 10 years at the time of screening.
  • Chinese participants who are born in China, has 2 Chinese biological parents, 4 Chinese grandparents as confirmed by the interview and has lived outside China for less than 10 years at the time of screening.
  • Have (BMI) between 18 and 30 kg/m2 and weigh at least 45 kg.
  • Healthy participants must have a Forced Expiratory Volume at first breath () ≥ 80% of the predicted value in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria at the Screening and admission visits.
  • Female participants must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • History or presence of disease which may put participant at risk because of participation in study.
  • Participant has an increased risk of infection.
  • History of other than superficial basal cell carcinoma, having a first degree relative with lung cancer or disease history suggesting abnormal immune function.
  • Has received any vaccine 30 days prior to first dose.
  • Has a body temperature of > 37.7°C on Day -1.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Known or suspected history of drug abuse, alcohol abuse or excessive intake of alcohol.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes, vaping, and nicotine replacement therapy) within the previous 6 months or has a smoking history of > 5 pack-years.
  • History of a serious or severe adverse reaction to AZD4604 or any of its additive constituents.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4604.
  • Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss> 500 mL during the 3 months prior to the Screening Visit.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12-lead safety ECG.
  • Female participants who are planning a pregnancy during the study period or within 1 month after the last dose of study intervention.
  • Abnormal vital signs at the Screening Visit, after 5 minutes supine rest.
  • History of any significant respiratory disorders such as asthma (a history of childhood asthma without symptoms or treatment after the age of 10 years is allowable), , or idiopathic pulmonary fibrosis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part 1a: AZD4604 (Dose 1) SAD

    Japanese participants will receive single dose of AZD4604 (Dose 1) via inhalation on Day 1.

    Drug: AZD4604

  • Experimental
    Part 1a: AZD4604 (Dose 2) SAD

    Japanese participants will receive single dose of AZD4604 (Dose 2) via inhalation on Day 1.

    Drug: AZD4604

  • Experimental
    Part 1a: AZD4604 (Dose 3) SAD

    Japanese participants will receive single dose of AZD4604 (Dose 3) via inhalation on Day 1.

    Drug: AZD4604

  • Placebo comparator
    Part 1a: Placebo

    Japanese participants will receive single dose of matching placebo to AZD4604 on Day 1.

    Drug: Placebo

  • Experimental
    Part 1b: AZD4604 (Dose 4) Multiple dose cohort

    Japanese participants will receive AZD4604 (Dose 4) via inhalation twice daily (BID) from Day 1 to Day 6 and a single dose on Day 7.

    Drug: AZD4604

  • Placebo comparator
    Part 1b: Placebo

    Japanese participants will receive matching placebo to AZD4604 BID from day 1 to day 6 and a single dose of placebo on Day 7.

    Drug: Placebo

  • Experimental
    Part 2a: AZD4604 (Dose 1) SAD

    Chinese participants will receive single dose of AZD4604 (Dose 1) via inhalation on Day 1.

    Drug: AZD4604

  • Experimental
    Part 2a: AZD4604 (Dose 3) SAD

    Chinese participants will receive single dose of AZD4604 (Dose 3) via inhalation on Day 1.

    Drug: AZD4604

  • Placebo comparator
    Part 2a: Placebo

    Chinese participants will receive single dose of matching placebo to AZD4604 on Day 1.

    Drug: Placebo

  • Experimental
    Part 2 b: AZD4604 (Dose 4) Multiple dose cohort

    Chinese participants will receive AZD4604 (Dose 4) via inhalation BID from Day 1 to Day 6 and a single dose on Day 7.

    Drug: AZD4604

  • Placebo comparator
    Part 2b: Placebo

    Chinese participants will receive placebo via inhalation BID from Day 1 to Day 6 and a single dose on Day 7.

    Drug: Placebo

Interventions

  • AZD4604 will be administered as Dry Powder Inhalation (DPI).

  • DrugPlacebo

    Placebo will be administered as DPI.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse event (AEs)

    To assess the safety and tolerability of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day -28 to 5 weeks (Parts 1a and 2a); Day -28 to 6 weeks (Parts 1b and 2b)

Secondary outcomes

  1. Maximum observed plasma (peak) drug concentration (Cmax)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  2. Time to reach peak or maximum observed concentration following drug administration (tmax)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  3. Terminal elimination rate constant (λz)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  4. Half-life associated with terminal slope of a semi-logarithmic concentration time curve (t½λz)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  5. Partial area under concentration-time curve from time 0 to 12 hours (AUC [0-12])

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); On Day 1 (Parts 1b and 2b)

  6. Partial area under concentration-time curve from time 0 to 24 hours (AUC [0-24])

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  7. Area under the plasma concentration curve from zero to last quantifiable concentration (AUClast)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  8. Area under the plasma concentration curve from zero to infinity (AUCinf)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a)

  9. Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  10. Volume of distribution (apparent) at steady state following extravascular administration based on terminal phase (Vz/F)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  11. Area under the plasma concentration time curve from zero to the last quantifiable concentration, divided by dose (AUClast/D)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  12. Area under the plasma concentration curve from zero to infinity, divided by dose (AUCinf/D)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a)

  13. Maximum observed plasma (peak) drug concentration, by dose (Cmax/D)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  14. The last time point at which the concentration is measured (tlast)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as single ascending doses (Parts 1a and 2a), and multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 7 (Parts 1a and 2a); From Day 1 to Day 13 (Parts 1b and 2b)

  15. Area under plasma concentration time curve from zero to end of dosing interval (AUCτ)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 13 (Parts 1b and 2b)

  16. Area under plasma concentration time curve from zero to end of dosing interval, by dose (AUCτ/D)

    To characterise the plasma PK of AZD4604 following inhaled administration of AZD4604 as multiple doses (Parts 1b and 2b).

    Time frame: From Day 1 to Day 13 (Parts 1b to 2b)

  17. Cough Severity self-assessment as measured by Visual Analogue Scale (VAS)

    The cough VAS is a brief and simple measure of cough severity. It consists of a 100 mm vertical scale on which the participant is asked to place a cross at the point that indicates the severity of his/her cough in the last 24 hours between "No cough" and "Worst cough ever". The position of the cross is measured from the "No cough" reference point. A minimal clinically important difference is considered to be a 17 mm change from previous.

    Time frame: From Day 1 to Day 8 (Parts 1b and 2b)

07

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Dec 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 25, 2024
StartActual
Jul 15, 2024
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06519968
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 25, 2024
Start date
Jul 15, 2024
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Last update
Nov 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Londamocitinib

Start the discussion